Vericiguat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan) and G-BA (Germany) recommended or restricted vericiguat, while ZIN (Netherlands) did not recommend it.
Every record falls within a 1.9-year window, 24 Jun 2021 to 12 May 2023 — a compressed review cycle.
TLV (Sweden) changed its position: not recommended on 11 Apr 2022, restricted by 29 Mar 2023, after a resubmission.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for vericiguat, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
4 distinct indication wordings are recorded for vericiguat by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess vericiguat, on 24 Jun 2021; PBAC (Australia) did not open a file until 2022 — a moderate spread of 1.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 12 dated records fall in 2021 alone.
4 of the 8 agencies here assessed vericiguat more than once, ZIN (Netherlands) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for vericiguat.
The full ledger for vericiguat reads 3 not recommended, 3 recommended, 1 advice and 1 restricted, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 12 May 2023 | GVS-advies herbeoordeling vericiguat (Verquvo®) voor de behandeling van volwassenen met chronisch hartfalen | advice published (GVS) | source |
| TLV (Sweden) | 29 Mar 2023 | Verquvo ingår i högkostnadsskyddet med begränsning. | restricted subsidy | source |
| PBAC (Australia) | 2022 | Chronic heart failure | Recommended | source |
| G-BA (Germany) | 3 Mar 2022 | Verquvo — benefit assessment §35a | added benefit: minor (hint) | source |
| SMC (Scotland) | 11 Oct 2021 | For treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV th… | not recommended | source |
7 further decisions for vericiguat, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- dapagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- sacubitril / valsartan — divergent outcome (not recommended vs recommended) on a shared indication
- empagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- eculizumab — also decided by ZIN in 2023Q2
- avacopan — also decided by ZIN in 2023Q2
- lanadelumab — also decided by ZIN in 2023Q2
Coverage: 12 decisions for vericiguat from 8 agencies, 2021 to 2023. Data to 7 Sep 2026. ATC class C01 — Cardiac therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.